FDA Panel Meets to Determine COVID Booster Shot Strategy

FDA Panel, Meets to Determine, COVID Booster Shot Strategy.

FDA Panel, Meets to Determine, COVID Booster Shot Strategy.

On April 6, United States Food and Drug Administration, advisers will meet to determine a plan for , the future of COVID-19 boosters.

NBC reports that the agency’s Vaccines and Related Biological Products Advisory Committee will develop a framework for long-term booster strategy.

.

The news comes one week after the FDA and the Centers for Disease Control and Prevention approved a second booster dose for people over the age of 50.

NBC reports that health experts have begun to question the practicality of getting multiple doses of a vaccine every few months to protect against COVID.

According to FDA scientists, the process for updating and distributing boosters could become like the flu shot.

.

Each year, scientists monitor influenza strains and select several that they predict will circulate widely to include in the annual vaccine.

.

Each year, scientists monitor influenza strains and select several that they predict will circulate widely to include in the annual vaccine.

.

Dr. William Schaffner, an infectious diseases expert at the Vanderbilt University Medical Center, suggests that a similar approach could work for COVID-19.

Dr. William Schaffner, an infectious diseases expert at the Vanderbilt University Medical Center, suggests that a similar approach could work for COVID-19.

However, Schaffner goes on to suggest that convincing the public to receive two separate annual vaccines could pose problems. .

Members of the scientific community have proposed that a two-in-one vaccine that protects against both the flu and COVID may be a viable solution.

.

Members of the scientific community have proposed that a two-in-one vaccine that protects against both the flu and COVID may be a viable solution.

.

NBC reports that Moderna has already begun work on a combination flu/COVID vaccine.